A method for chemical separation of cannabinoids includes: (i) providing a starting organic solvent solution that contains a mixture of cannabinoid acids, (ii) using an aqueous basic solution to remove a portion of the cannabinoid acids from the mixture of cannabinoid acids in the starting organic solvent solution by converting the portion of the cannabinoid acids to cannabinoid carboxylate salts that solubilize in the an aqueous basic solution, (iii) separating the aqueous basic solution in (ii) from the starting organic solvent, (iv) combining the aqueous solution from (iii) with new organic solvent to produce a combined solution, (v) acidifying the combined solution to extract the cannabinoid acids from the aqueous solution to the organic solvent, (vi) separating the organic solvent of (v) from the aqueous solution, and (vii) evaporating the organic solvent of (vi) to leave product cannabinoid acids.

A method for chemical separation of cannabinoids includes: (i) providing a starting organic solvent solution that contains a mixture of cannabinoid acids, (ii) using an aqueous basic solution to remove a portion of the cannabinoid acids from the mixture of cannabinoid acids in the starting organic solvent solution by converting the portion of the cannabinoid acids to cannabinoid carboxylate salts that solubilize in the an aqueous basic solution, (iii) separating the aqueous basic solution in (ii) from the starting organic solvent, (iv) combining the aqueous solution from (iii) with new organic solvent to produce a combined solution, (v) acidifying the combined solution to extract the cannabinoid acids from the aqueous solution to the organic solvent, (vi) separating the organic solvent of (v) from the aqueous solution, and (vii) evaporating the organic solvent of (vi) to leave product cannabinoid acids.

Disclosed are compounds that can modulate DDAH and the amount of asymmetric dimethylarginine (ADMA) in a subject. Also provided are pharmaceutical compositions comprising these compounds, as well as methods of using these compositions to treat and/or prevent diseases associated with elevated or low levels of DDAH and ADMA.

Disclosed are compounds that can modulate DDAH and the amount of asymmetric dimethylarginine (ADMA) in a subject. Also provided are pharmaceutical compositions comprising these compounds, as well as methods of using these compositions to treat and/or prevent diseases associated with elevated or low levels of DDAH and ADMA.

Disclosed are compounds that can modulate DDAH and the amount of asymmetric dimethylarginine (ADMA) in a subject. Also provided are pharmaceutical compositions comprising these compounds, as well as methods of using these compositions to treat and/or prevent diseases associated with elevated or low levels of DDAH and ADMA.

Disclosed are compounds that can modulate DDAH and the amount of asymmetric dimethylarginine (ADMA) in a subject. Also provided are pharmaceutical compositions comprising these compounds, as well as methods of using these compositions to treat and/or prevent diseases associated with elevated or low levels of DDAH and ADMA.

A compound represented by formula I or II. X represents a mono substituent on a benzene ring, and is selected from H, I, Br, Cl, F, CN, an amino, and a derivative thereof; R.sub.1 is a C.sub.2-10 alkyl, C.sub.2-10 alkyl substituted by cyclopropane or fluorine, except n-butyl; and M is an amine ion or metal ion.

The present invention provides an agent for the prophylactic or treatment of diabetes, diabetic complications, insulin resistance syndrome, metabolic syndrome, hyperglycemia, dyslipidemia, atherosclerosis, cardiac failure, cardiomyopathy, myocardial ischemia, brain ischemia, cerebral apoplexy, pulmonary hypertension, hyperlactacidemia, mitochondrial disease, mitochondrial encephalomyopathy or cancer, namely, a PDHK inhibitor and the like. A compound represented by the following formula [I] or a pharmaceutically acceptable salt thereof, or a solvate thereof:

##STR00001##

wherein each symbol is as defined in the specification.

The present invention provides an agent for the prophylactic or treatment of diabetes, diabetic complications, insulin resistance syndrome, metabolic syndrome, hyperglycemia, dyslipidemia, atherosclerosis, cardiac failure, cardiomyopathy, myocardial ischemia, brain ischemia, cerebral apoplexy, pulmonary hypertension, hyperlactacidemia, mitochondrial disease, mitochondrial encephalomyopathy or cancer, namely, a PDHK inhibitor and the like. A compound represented by the following formula [I] or a pharmaceutically acceptable salt thereof, or a solvate thereof:

##STR00001##

wherein each symbol is as defined in the specification.

The present invention relates to novel cycloalkyl-hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, Syndrome X, thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.